tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Diseases D008107 31 associated lipids
Long QT Syndrome D008133 10 associated lipids
Lung Abscess D008169 1 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphocele D008210 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphoma D008223 18 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Malacoplakia D008287 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Mastocytosis D008415 5 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinitis D008480 2 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Meningococcal Infections D008589 3 associated lipids
Meningoencephalitis D008590 4 associated lipids
Metaplasia D008679 7 associated lipids
Mite Infestations D008924 1 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mouth Diseases D009059 5 associated lipids
Moyamoya Disease D009072 1 associated lipids
Multiple Myeloma D009101 13 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Mutism D009155 1 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycoses D009181 18 associated lipids
Myelitis D009187 1 associated lipids
Myxedema D009230 2 associated lipids
Nail Diseases D009260 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nephritis D009393 19 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Schreiber SL et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. 1991 Transplant. Proc. pmid:1721293
Nakata S et al. Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. 1991 Transplant. Proc. pmid:1721325
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Van Thiel DH et al. Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1721357
Burman K and Crawford DH Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. 1991 Lancet pmid:1703259
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Schmidt RJ et al. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721390
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Goebl MG The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. 1991 Cell pmid:1706222
de Paulis A et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. 1991 J. Immunol. pmid:1706398
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Thomson AW et al. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. 1991 Transplant. Proc. pmid:1721452
Miyahara H et al. Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. 1991 Clin. Immunol. Immunopathol. pmid:1712688
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Pourtier-Manzanedo A et al. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. 1991 Anticancer Drugs pmid:1724925
Gailliot FP et al. Fluidized bed adsorption for whole broth extraction. 1990 Sep-Oct Biotechnol. Prog. pmid:1366874
Naouri A and Tissot E [Indications for liver transplantation in adults]. 1990 Jun-Jul J Chir (Paris) pmid:1698800
MacLeod AM and Thomson AW [FK-506. A new immunosuppressive drug]. 1990 Jul-Sep Medicina (Firenze) pmid:1706817
Wasik M et al. Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. 1990 Jul-Aug Immunopharmacology pmid:1699911
Jain AB et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. 1990 Transplant. Proc. pmid:1689900
Fung JJ et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. 1990 Transplant. Proc. pmid:1689901
Zeevi A et al. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. 1990 Transplant. Proc. pmid:1689902
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Ericzon BG et al. Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. 1990 Transplant. Proc. pmid:1689905
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Maki N et al. Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin. 1990 Proc. Natl. Acad. Sci. U.S.A. pmid:1695378
Doe SE et al. Early effects of the immunosuppressive drug FK-506 on signal transduction in lymphocytes. 1990 Biochem. Soc. Trans. pmid:1695581
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Suzuki S et al. In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. 1990 Heart Vessels pmid:1699922
Bierer BE et al. Probing immunosuppressant action with a nonnatural immunophilin ligand. 1990 Science pmid:1700475
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Wicker LS et al. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. 1990 Eur. J. Immunol. pmid:1700753
Sigal NH et al. Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. 1990 Biochem. Pharmacol. pmid:1700909
Hara S et al. The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. 1990 Clin. Immunol. Immunopathol. pmid:1700936
Murase N et al. Effect of FK 506 on spontaneous diabetes in BB rats. 1990 Diabetes pmid:1700959
Kawashima H and Mochizuki M Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. 1990 Exp. Eye Res. pmid:1701148
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Ni M et al. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. 1990 Autoimmunity pmid:1717008